FibroBiologics, Inc. Net Fee Amt
FibroBiologics, Inc. (FBLG) had Net Fee Amt of $1.44 thousand as of 2026-07-09, per its S-3 filed 2026-07-10.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-10
- 2026-07-09: Net Fee Amt $1.44K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-09 | $1.44K S-3 · filed 2026-07-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 |